Key facts
- Atommap’s last known valuation is $104.1M (Mar 2026).
- It has raised $38.2M across 2 recorded rounds; the latest was Early Stage VC ($31.1M) in Mar 2026.
- Notable investors include Sutter Hill Ventures.
- Atommap has filed 2 Form Ds with the SEC since 2023, most recently Mar 2026 ($31.1M sold to 29 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Atommap
Funding rounds
2 roundsAbout Atommap
Developer of a computational molecular design system intended for drug discovery and therapeutic development. The company's platform combines physics-based simulations, machine learning models, and high-performance computing to generate and evaluate molecular designs, simulate protein-protein interactions, predict binding affinities, and optimize therapeutic degraders, enabling pharmaceutical researchers and biotech companies to identify novel drug candidates, accelerate discovery timelines, and reduce development costs for previously intractable biological targets.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2023
- Employees
- 7
- Website
- atommap.com/
- Ownership
- Privately Held (backing)
Atommap doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Atommap shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Atommap in its N-PORT filings yet. We sweep new filings monthly.